Phaseline

Targets › IL10

IL10 (Interleukin-10): drug programs, companies and trials

3 programs from 3 companies in 3 trials: 3 Phase 1; Oncology, Immunology; next expected readout Dec 2026.

Major immune regulatory cytokine that acts on many cells of the immune system where it has profound anti-inflammatory functions, limiting excessive tissue disruption caused by inflammation. Mechanistically, IL10 binds to its heterotetrameric receptor comprising IL10RA and IL10RB leading to JAK1 and STAT2-mediated phosphorylation of STAT3. (UniProt, P22301)

Open in Phaseline: the race on IL10, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Second Affiliated Hospital, Zhejiang University, School of Medicineanti-CD19 IL10/IL15 CAR-NK
anti-CD19 chimeric antigen receptor NK cells engineered to co-express IL-10 and IL-15
CD19, IL10, IL15Phase 1B-cell Non Hodgkin LymphomaDec 2026
L & L Bio Co., Ltd., Ningbo, ChinaLB4330
anti-claudin18.2/IL-10 fusion protein
CLDN18, IL10Phase 1Solid TumorDec 2026
PhilogenF8IL10
Engineered human interleukin-10 fused to F8 antibody fragment targeting fibronectin
IL10Phase 1Rheumatoid Arthritis (RA)Sep 2028

Conditions

B-cell Non Hodgkin Lymphoma (1) Rheumatoid Arthritis (RA) (1) Solid Tumor (1)

Modalities

small molecule (2), protein or peptide (1)

Companies

Second Affiliated Hospital, Zhejiang University, School of Medicine (1) Philogen (1) L & L Bio Co., Ltd., Ningbo, China (1)

Related targets

CD19 (1) IL15 (1) CLDN18 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.